Immunoadsorption of anti-von willebrand factor cleaving protease antibodies
AssigneesBaxter International Inc., Baxter Healthcare S.A.
InventorsFriedrich Scheiflinger, Barbara Plaimauer, Gerhard Antoine
Life of this patent
Estimating the term…
Abstract
This invention relates to adsorbents and methods for highly selective removal of anti-von Willebrand Factor-cleaving protease antibodies (“anti-vWF-cp-abs”) from human plasma using human von Willebrand Factor-cleaving protease (“hvWF-cp”) or fragments thereof as affinity ligands. The adsorbents can be used for treating disorders associated with the occurrence of anti-vWF-cp-abs in patients, such as thromboembolic diseases.
Claims15
An adsorbent for selective removal of anti-von Willebrand Factor cleaving protease antibodies from human plasma, where the adsorbent comprises a fragment of human von-Willebrand Factor-cleaving protease coupled to an inert matrix material, said fragment having at least one functionally active epitope recognized by said anti-von Willebrand Factor-cleaving protease antibodies under physiological conditions, wherein said fragment is selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, and SEQ ID NO:5.
A method for selective removal of anti-von Willebrand Factor-cleaving protease antibodies from human plasma, comprising the steps of:
- (a) providing a plasma from whole blood from a patient having a disorder associated with occurrence of anti-von Willebrand Factor-cleaving protease antibodies;
- (b) subjecting said plasma to an affinity chromatography using an adsorbent where the adsorbent comprises a fragment of human von-Willebrand Factor-cleaving protease coupled to an inert matrix material, said fragment having at least one functionally active epitope recognized by said anti-von Willebrand Factor-cleaving protease antibodies under physiological conditions, wherein said fragment is selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, and SEQ ID NO:5;
- wherein the affinity chromatography is performed under physiological conditions in which the antibodies bind to human von Willebrand Factor-cleaving protease;
- and
- (c) collecting a flow-through fraction which is essentially devoid of anti-von Willebrand Factor-cleaving protease antibodies.
Dependencies are inferred from the claim text.